Newsroom Bayer - Search results

(Please check against delivery)Werner Baumann,Chairman of the Board of Management (CEO) of Bayer AG:Good morning, everybody! On behalf of the entire Board of Management, I would like to wish you all a very warm welcome to our virtual Financial News Conference.Today, we will be looking back together ... Read more

stainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. For more information, go to leaps.bayer.com.Follow us on twitter.com/bayerForward-Looking StatementsThis release may contain forward-looking statements based on current assumptio ... Read more

a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. For more information, go to leaps.bayer.com.About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech an ... Read more

Research Triangle Park, N.C. (January 9, 2023) - Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, t ... Read more

(Please check against delivery)Werner Baumann:I would also like to welcome you to today’s conference call on the third quarter of 2022. Let me start by summarizing the key developments in the third quarter together with Wolfgang Nickl. We maintained our strong business performance across all ... Read more

op sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. For more information, go to leaps.bayer.com.About NuCicerNuCicer is an agri-food technology company pioneering ultra-high protein chickpea varieties that enable scalable, sustain ... Read more

Monheim / Germany, August 1, 2022 – Bayer, Bunge (NYSE: BG) and Chevron U.S.A. Inc. (Chevron), a subsidiary of Chevron Corporation (NYSE: CVX), have signed a shareholders’ agreement in connection with Bayer’s acquisition of a 65 percent majority ownership of the winter oilseed producer CoverCr ... Read more

Berlin / Boston, June 29, 2022 - Bayer AG announced today the opening of its new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), expanding further the company’s footprint into one of the world’s most innovative pharmaceutical research and development ... Read more

Berlin, June 8, 2022 - Bayer AG announced today that BlueRock Therapeutics LP (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. This move comes as part of the ... Read more

CAMBRIDGE, Mass., May 31, 2022 - BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinso ... Read more